Scarica l'app Stockscreener
8.54
0.12%
-0.01
Precedente Chiudi:
$8.55
Aprire:
$8.55
Volume 24 ore:
755.34K
Relative Volume:
0.20
Capitalizzazione di mercato:
$802.02M
Reddito:
$324.00K
Utile/perdita netta:
$-82.10M
Rapporto P/E:
-9.1828
EPS:
-0.93
Flusso di cassa netto:
$-69.18M
1 W Prestazione:
-0.12%
1M Prestazione:
+0.47%
6M Prestazione:
+874.66%
1 anno Prestazione:
+834.46%
Intervallo 1D:
$8.54
$8.55
Intervallo di 1 settimana:
$8.53
$8.55
Portata 52W:
$0.75
$8.55
Chimerix Inc Stock (CMRX) Company Profile
Nome
Chimerix Inc
Settore
Industria
Telefono
919.806.1074
Indirizzo
2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC
Confronta CMRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CMRX
Chimerix Inc
|
8.54 | 802.02M | 324.00K | -82.10M | -69.18M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.82 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.19 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
600.32 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.41 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
253.34 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Chimerix Inc Stock (CMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-05-23 | Iniziato | Robert W. Baird | Outperform |
| 2022-09-07 | Iniziato | CapitalOne | Overweight |
| 2021-04-29 | Iniziato | Maxim Group | Buy |
| 2021-04-23 | Ripresa | Cowen | Outperform |
| 2021-03-31 | Iniziato | Jefferies | Buy |
| 2021-03-31 | Iniziato | Wedbush | Outperform |
| 2018-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-02-02 | Iniziato | H.C. Wainwright | Buy |
| 2016-08-09 | Reiterato | FBR Capital | Mkt Perform |
| 2016-02-23 | Downgrade | Barclays | Overweight → Equal Weight |
| 2016-02-23 | Reiterato | FBR Capital | Mkt Perform |
| 2016-02-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2016-02-22 | Downgrade | Citigroup | Buy → Neutral |
| 2015-12-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2015-12-28 | Downgrade | FBR Capital | Outperform → Mkt Perform |
| 2015-12-28 | Reiterato | Piper Jaffray | Overweight |
| 2015-12-17 | Iniziato | UBS | Buy |
| 2015-10-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2015-09-03 | Iniziato | Citigroup | Buy |
| 2015-08-18 | Iniziato | FBR Capital | Outperform |
| 2015-08-06 | Reiterato | Brean Capital | Buy |
| 2015-05-11 | Reiterato | Brean Capital | Buy |
| 2015-03-04 | Iniziato | Barclays | Overweight |
| 2015-02-12 | Reiterato | Stifel | Buy |
| 2014-12-31 | Reiterato | Brean Capital | Buy |
| 2014-07-08 | Ripresa | Brean Capital | Buy |
Mostra tutto
Chimerix Inc Borsa (CMRX) Ultime notizie
Jazz Pharmaceuticals Acquires Chimerix for $935M - Contract Pharma
Jazz Pharmaceuticals Completes $935 Million Acquisition of Chimerix - marketscreener.com
Jazz Pharmaceuticals acquires Chimerix for $935 million By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals (JAZZ) Completes Acquisition of Chimerix - StreetInsider
Jazz Pharmaceuticals Completes Acquisition of Chimerix - TipRanks
Jazz Pharmaceuticals acquires Chimerix for $935 million - Investing.com
Jazz Pharmaceuticals Completes Acquisition of Chimerix | JAZZ Stock News - GuruFocus
Jazz's $935M Chimerix Buyout Targets First-Ever Treatment for Rare Brain Cancer, FDA Verdict Looms - Stock Titan
Chimerix stock soars to 52-week high, hits $8.54 By Investing.com - Investing.com South Africa
Chimerix stock soars to 52-week high, hits $8.54 - Investing.com
Unlocking Investment Potential Discover the Power of Magical Signals Bullish Signal - AInvest
Top 3 Health Care Stocks That May Crash In Q2 - Benzinga
Chimerix stock soars to 52-week high, hits $8.53 By Investing.com - Investing.com Australia
Chimerix stock soars to 52-week high, hits $8.53 - Investing.com
Jazz Pharmaceuticals, Chimerix HSR waiting period expired on March 31 - MLex
Is Chimerix Inc. (CMRX) the Best Performing NASDAQ Stock So Far in 2025? - Insider Monkey
11 Best Performing NASDAQ Stocks So Far in 2025 - Insider Monkey
Exploring US High Growth Tech Stocks In March 2025 - simplywall.st
Chimerix Inc. (NASDAQ:CMRX) Amazing Performance So Far In 2025 - Yahoo Finance
11 Best Performing Stocks So Far In 2025 - Insider Monkey
Chimerix Reports 2024 Losses Amid Acquisition News - TipRanks
Chimerix earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada
Chimerix Inc Reports Q4 2024 EPS of -$0.25, Beating Estimates; R - GuruFocus.com
The buildup to Chimerix's $935M exit to Jazz, with more than half a dozen parties intrigued - Endpoints News
Chimerix: Q4 Earnings Snapshot - mySA
Chimerix Inc. (CMRX) reports earnings - Quartz
CHIMERIX INC SEC 10-K Report - TradingView
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results - The Manila Times
Chimerix Reports Earnings as $935M Jazz Buyout and FDA Drug Review Advance - StockTitan
Investment Analysts’ Recent Ratings Updates for Chimerix (CMRX) - Defense World
Chimerix stock soars to 52-week high, hits $8.47 By Investing.com - Investing.com Australia
Chimerix stock soars to 52-week high, hits $8.47 - Investing.com India
Ireland: Jazz adds to oncology pipeline with Chimerix - Investors in Healthcare
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, BLBX, CMRX, WBA on Behalf of Shareholders - GlobeNewswire Inc.
Kuehn Law Encourages BRDG, CMRX, WBA and SYTA Investors to Contact Law Firm - The Malaysian Reserve
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (NasdaqTSVT), Bridge Investment Group Holdings Inc. (NYSEBRDG), Chimerix, Inc. (NasdaqCMRX), 180 Degree Capital Corp. (Nasda - Morningstar
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX, WBA, BLUE on Behalf of Shareholders - Victoria Advocate
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisi - WICZ
Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - Financial Content
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc.CMRX - Business Wire
Why Chimerix, Inc. (CMRX) Soared Last Week - Insider Monkey
Chimerix Inc Azioni (CMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Chimerix Inc Azioni (CMRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Andriole Michael T. | PRESIDENT AND CEO |
Feb 13 '25 |
Sale |
4.52 |
7,370 |
33,282 |
609,603 |
| Alrutz Michael Albert | SVP AND GENERAL COUNSEL |
Feb 13 '25 |
Sale |
4.52 |
1,600 |
7,226 |
213,596 |
| Jakeman David | VP OF FINANCE AND ACCOUNTING |
Feb 13 '25 |
Sale |
4.53 |
300 |
1,360 |
148,987 |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER |
Feb 13 '25 |
Sale |
4.51 |
2,260 |
10,196 |
172,977 |
1.75%
2.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):